GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » iSpecimen Inc (NAS:ISPC) » Definitions » Liabilities-to-Assets

iSpecimen (iSpecimen) Liabilities-to-Assets : 0.38 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is iSpecimen Liabilities-to-Assets?

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. iSpecimen's Total Liabilities for the quarter that ended in Dec. 2023 was $6.08 Mil. iSpecimen's Total Assets for the quarter that ended in Dec. 2023 was $15.82 Mil. Therefore, iSpecimen's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2023 was 0.38.


iSpecimen Liabilities-to-Assets Historical Data

The historical data trend for iSpecimen's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

iSpecimen Liabilities-to-Assets Chart

iSpecimen Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Liabilities-to-Assets
Get a 7-Day Free Trial 6.39 5.39 0.17 0.18 0.38

iSpecimen Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Liabilities-to-Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.18 0.18 0.16 0.22 0.38

Competitive Comparison of iSpecimen's Liabilities-to-Assets

For the Diagnostics & Research subindustry, iSpecimen's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


iSpecimen's Liabilities-to-Assets Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, iSpecimen's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where iSpecimen's Liabilities-to-Assets falls into.



iSpecimen Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

iSpecimen's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Liabilities-to-Assets (A: Dec. 2023 )=Total Liabilities/Total Assets
=6.078/15.819
=0.38

iSpecimen's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2023 is calculated as

Liabilities-to-Assets (Q: Dec. 2023 )=Total Liabilities/Total Assets
=6.078/15.819
=0.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


iSpecimen  (NAS:ISPC) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.


iSpecimen Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of iSpecimen's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


iSpecimen (iSpecimen) Business Description

Traded in Other Exchanges
N/A
Address
450 Bedford Street, Lexington, MA, USA, 02420
iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research, with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas; Europe, the Middle East, Africa, and Asia Pacific, which majority, comes from the Americas.
Executives
Benjamin Bielak officer: Chief Information Officer 450 BEDFORD STREET, LEXINGTON MA 02420
Tracy Curley officer: Chief Financial Officer 450 BEDFORD STREET, LEXINGTON MA 02420
Joseph J. Basile director 450 BEDFORD STREET, LEXINGTON MA 02420
Andrew L. Ross director, 10 percent owner 450 BEDFORD STREET, LEXINGTON MA 02420
Gullans Steven R. Ph.d. director C/O EXCEL VENTURE MANAGEMENT, LLC, 800 BOYLSTON ST., STE 2825, BOSTON MA 02199
John L Brooks director 100 LOWDER BROOK DRIVE SUITE 2500, WESTWOOD MA 02090
Obf Investments, Llc 10 percent owner 450 BEDFORD STREET, LEXINGTON MA 02420
Margaret H. Lawrence director 450 BEDFORD STREET, LEXINGTON MA 02420
George H. Scholl director 450 BEDFORD STREET, LEXINGTON MA 02420
Christopher Ianelli director, officer: CEO, President 450 BEDFORD STREET, LEXINGTON MA 02420
Jill Mullan director, officer: COO, Secretary, Treasurer 450 BEDFORD STREET, LEXINGTON MA 02420